JP2008540445A5 - - Google Patents

Download PDF

Info

Publication number
JP2008540445A5
JP2008540445A5 JP2008510224A JP2008510224A JP2008540445A5 JP 2008540445 A5 JP2008540445 A5 JP 2008540445A5 JP 2008510224 A JP2008510224 A JP 2008510224A JP 2008510224 A JP2008510224 A JP 2008510224A JP 2008540445 A5 JP2008540445 A5 JP 2008540445A5
Authority
JP
Japan
Prior art keywords
composition
site
aav vector
aav2
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008510224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540445A (ja
JP5829372B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/017242 external-priority patent/WO2006119458A1/en
Publication of JP2008540445A publication Critical patent/JP2008540445A/ja
Publication of JP2008540445A5 publication Critical patent/JP2008540445A5/ja
Application granted granted Critical
Publication of JP5829372B2 publication Critical patent/JP5829372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008510224A 2005-05-02 2006-05-02 神経代謝性疾患のための遺伝子治療 Active JP5829372B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67705705P 2005-05-02 2005-05-02
US60/677,057 2005-05-02
US68580805P 2005-05-31 2005-05-31
US60/685,808 2005-05-31
PCT/US2006/017242 WO2006119458A1 (en) 2005-05-02 2006-05-02 Gene therapy for neurometabolic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013201138A Division JP2014037418A (ja) 2005-05-02 2013-09-27 神経代謝性疾患のための遺伝子治療

Publications (3)

Publication Number Publication Date
JP2008540445A JP2008540445A (ja) 2008-11-20
JP2008540445A5 true JP2008540445A5 (enExample) 2009-07-09
JP5829372B2 JP5829372B2 (ja) 2015-12-09

Family

ID=37308324

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008510224A Active JP5829372B2 (ja) 2005-05-02 2006-05-02 神経代謝性疾患のための遺伝子治療
JP2013201138A Pending JP2014037418A (ja) 2005-05-02 2013-09-27 神経代謝性疾患のための遺伝子治療
JP2015197051A Active JP6338560B2 (ja) 2005-05-02 2015-10-02 神経代謝性疾患のための遺伝子治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013201138A Pending JP2014037418A (ja) 2005-05-02 2013-09-27 神経代謝性疾患のための遺伝子治療
JP2015197051A Active JP6338560B2 (ja) 2005-05-02 2015-10-02 神経代謝性疾患のための遺伝子治療

Country Status (13)

Country Link
US (2) US10632213B2 (enExample)
EP (4) EP2420256B1 (enExample)
JP (3) JP5829372B2 (enExample)
CN (4) CN104306986A (enExample)
AT (1) ATE525092T1 (enExample)
AU (1) AU2006243776A1 (enExample)
BR (1) BRPI0611379A2 (enExample)
CA (2) CA2607173C (enExample)
ES (1) ES2887076T3 (enExample)
IL (2) IL187078A (enExample)
PL (4) PL3058959T3 (enExample)
PT (4) PT2420256T (enExample)
WO (1) WO2006119458A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3302529B2 (ja) 1995-04-28 2002-07-15 株式会社クボタ ポンプ吸水槽の整流装置
DK1879623T3 (da) * 2005-05-02 2012-12-17 Genzyme Corp Genterapi til rygmarvssygdomme
EP2420256B1 (en) 2005-05-02 2016-06-22 Genzyme Corporation Gene therapy for neurometabolic disorders
EP2489733B1 (en) 2006-06-07 2019-02-13 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
EP3252161B1 (en) 2007-06-06 2021-11-17 Genzyme Corporation Gene therapy for lysosomal storage diseases
EP2687609B1 (en) 2008-11-10 2017-01-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for treating solid tumor
PL4342992T3 (pl) 2009-05-02 2025-09-22 Genzyme Corporation Terapia genowa dla zaburzeń neurodegeneracyjnych
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
WO2012145646A1 (en) * 2011-04-20 2012-10-26 Miguel Sena-Esteves Methods for the treatment of tay-sachs disease, sandhoff disease, and gmi-gangliosidosis
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
SG10202007103TA (en) 2014-11-05 2020-09-29 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
KR20230169197A (ko) 2014-11-14 2023-12-15 보이저 테라퓨틱스, 인크. 근위축성 측삭 경화증(als)을 치료하는 조성물 및 방법
CN112375760A (zh) 2014-11-14 2021-02-19 沃雅戈治疗公司 调节性多核苷酸
US11319555B2 (en) 2014-11-20 2022-05-03 Duke University Compositions, systems and methods for cell therapy
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
HUE057272T2 (hu) * 2015-02-10 2022-04-28 Genzyme Corp Vírusrészecskék fokozott bevitele a csíkolt testbe és az agykéregbe
CN112472796B (zh) * 2015-03-26 2024-12-24 上海澳宗生物科技有限公司 使用p75ecd和/或p75诊断或治疗神经障碍的方法
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US11027024B2 (en) 2015-05-29 2021-06-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
CN117904112A (zh) 2016-05-18 2024-04-19 沃雅戈治疗公司 调节性多核苷酸
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN119491003A (zh) 2017-05-05 2025-02-21 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
IL271193B2 (en) 2017-06-07 2025-01-01 Regeneron Pharma Preparations and methods for internalizing enzymes
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
AU2018352236B2 (en) 2017-10-16 2025-04-10 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
WO2019157224A1 (en) 2018-02-07 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
AU2019269685B2 (en) 2018-05-17 2025-12-04 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
SG11202103151RA (en) 2018-09-28 2021-04-29 Voyager Therapeutics Inc Frataxin expression constructs having engineered promoters and methods of use thereof
KR20240126916A (ko) * 2023-02-14 2024-08-22 경북대학교 산학협력단 Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
ATE437232T1 (de) 1993-10-25 2009-08-15 Canji Inc Rekombinanter adenoviren-vektor und verfahren zur verwendung
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JPH10501686A (ja) 1994-04-13 1998-02-17 ザ ロックフェラー ユニヴァーシティ 神経系の細胞へのdnaのaav仲介送達
WO1997039789A1 (en) 1996-04-22 1997-10-30 Medtronic, Inc. Two-stage angled venous cannula
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
WO2001036603A2 (en) * 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
WO2002024932A2 (en) 2000-09-18 2002-03-28 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
CA2469785C (en) 2001-12-17 2014-04-22 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
WO2003055983A2 (en) 2001-12-21 2003-07-10 The Salk Institute For Biological Studies Targeted retrograde gene delivery to motor neurons
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
AU2003220115A1 (en) * 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
EP1620133B1 (en) * 2003-05-01 2015-12-09 Genzyme Corporation Gene therapy for neurometabolic disorders
US20040258666A1 (en) * 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
US7740168B2 (en) 2003-08-18 2010-06-22 Visa U.S.A. Inc. Method and system for generating a dynamic verification value
AU2003272868A1 (en) 2003-10-15 2005-04-27 Agtc Gene Technology Company Ltd. Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors
EP1716870A1 (en) 2005-04-29 2006-11-02 Bracco Imaging S.p.A. MRI contrast agents endowed with concentration independent responsiveness
EP2420256B1 (en) 2005-05-02 2016-06-22 Genzyme Corporation Gene therapy for neurometabolic disorders
DK1879623T3 (da) 2005-05-02 2012-12-17 Genzyme Corp Genterapi til rygmarvssygdomme
HUE041928T2 (hu) 2006-02-08 2019-06-28 Genzyme Corp Génterápia A-típusú Niemann-Pick-betegségre
EP2709991B1 (en) 2011-05-16 2020-09-02 Genzyme Corporation Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia
TWI821227B (zh) 2017-12-22 2023-11-11 美商健臻公司 胺甲喋呤誘發的免疫耐受性之生物標記

Similar Documents

Publication Publication Date Title
JP2008540445A5 (enExample)
Ling et al. AAV-based in vivo gene therapy for neurological disorders
US11957765B2 (en) Gene therapy for neurometabolic disorders
Zhang et al. Several rAAV vectors efficiently cross the blood–brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system
JP2009526067A5 (enExample)
Murlidharan et al. Biology of adeno-associated viral vectors in the central nervous system
Cheng et al. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders
JP6312771B2 (ja) 神経代謝性疾患についての遺伝子治療
EP3498851B1 (en) Cns gene delivery using peripheral administration of aav vectors
TWI547288B (zh) 用於治療疾病之載體及序列
Miyake et al. Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors
JP2016503405A5 (enExample)
EA036394B1 (ru) Псевдотипированный вектор на основе аденоассоциированного вируса aav-5 для генной терапии неврологических заболеваний
Hironaka et al. Enzyme replacement in the CSF to treat metachromatic leukodystrophy in mouse model using single intracerebroventricular injection of self-complementary AAV1 vector
Ruzo et al. Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice
Gomez Limia et al. Emerging perspectives on gene therapy delivery for neurodegenerative and neuromuscular disorders
WO2023093905A1 (zh) Aadc、gdnf多核苷酸及其用于治疗帕金森病
Cardone Prospects for gene therapy in inherited neurodegenerative diseases
US20230277687A1 (en) Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
Miyake et al. Gene delivery into the central nervous system (CNS) using AAV vectors
Weismann Approaches and Considerations Towards a Safe and Effective Adeno-Associated Virus Mediated Therapeutic Intervention for GM1-Gangliosidosis: A Dissertation
Weismann Let us know how access to this document benefits you.
Murlidharan et al. Gene Therapy of CNS Disorders Using Recombinant AAV Vectors
Cearley Adeno-associated virus vector mediated correction of a neurogenetic disease: Influence of the vector capsid on dispersal of a therapeutic gene within the central nervous system